Tumor hypoxia: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{CMG}} | |||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
'''Tumor hypoxia''' is the situation where [[tumor]] [[cell (biology)|cells]] have been deprived of [[oxygen]]. Hypoxic tumor cells usually resist to [[radiotherapy]] and [[chemotherapy]] <ref> W. A. Denny, Prodrug strategies in cancer therapy, Eur. J. Med. Chem., 2001, 36, 577–595</ref> as they can be made more susceptible to treatment by increasing the amount of oxygen in them, but [[bioreductive prodrugs]] play a significant part in dealing with this kind of cells: they can kill the oxygen-deficient tumor cells selectively as [[hypoxic cytotoxins]]. Study of tumors in such conditions was pioneered by [[Louis Harold Gray|Dr L. H. Gray]]. | '''Tumor hypoxia''' is the situation where [[tumor]] [[cell (biology)|cells]] have been deprived of [[oxygen]]. Hypoxic tumor cells usually resist to [[radiotherapy]] and [[chemotherapy]] <ref> W. A. Denny, Prodrug strategies in cancer therapy, Eur. J. Med. Chem., 2001, 36, 577–595</ref> as they can be made more susceptible to treatment by increasing the amount of oxygen in them, but [[bioreductive prodrugs]] play a significant part in dealing with this kind of cells: they can kill the oxygen-deficient tumor cells selectively as [[hypoxic cytotoxins]]. Study of tumors in such conditions was pioneered by [[Louis Harold Gray|Dr L. H. Gray]]. | ||
| Line 11: | Line 11: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
* <references/> | * <references/> | ||
[[Category:Oxygen]] | [[Category:Oxygen]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 15:04, 30 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
WikiDoc Resources for Tumor hypoxia |
|
Articles |
|---|
|
Most recent articles on Tumor hypoxia Most cited articles on Tumor hypoxia |
|
Media |
|
Powerpoint slides on Tumor hypoxia |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tumor hypoxia at Clinical Trials.gov Trial results on Tumor hypoxia Clinical Trials on Tumor hypoxia at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tumor hypoxia NICE Guidance on Tumor hypoxia
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tumor hypoxia Discussion groups on Tumor hypoxia Patient Handouts on Tumor hypoxia Directions to Hospitals Treating Tumor hypoxia Risk calculators and risk factors for Tumor hypoxia
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tumor hypoxia |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Tumor hypoxia is the situation where tumor cells have been deprived of oxygen. Hypoxic tumor cells usually resist to radiotherapy and chemotherapy [1] as they can be made more susceptible to treatment by increasing the amount of oxygen in them, but bioreductive prodrugs play a significant part in dealing with this kind of cells: they can kill the oxygen-deficient tumor cells selectively as hypoxic cytotoxins. Study of tumors in such conditions was pioneered by Dr L. H. Gray.
It can also be a result of the high degree of cell proliferation undergone in tumor tissue, causing a higher cell density, and thus taxing the local oxygen supply.
See also
References
- ↑ W. A. Denny, Prodrug strategies in cancer therapy, Eur. J. Med. Chem., 2001, 36, 577–595